Research Article
Thyroid Dysfunction after Gonadotropin-Releasing Hormone Agonist Administration in Women with Thyroid Autoimmunity
Table 2
Characteristics of the patients, according to subgroups A1 and A2.
| | Parameter | Subgroup A1 (n = 10) | Subgroup A2 (n = 24) | |
| | Age (y) | 39 (6) | 35 (7) | 0.0292 | | BMI (kg/m2) | 24.0 (7.25) | 23.5 (3.75) | 0.5406 | | TSH at T0 (mIU/L) | 2.17 (1.35) | 2.15 (1.43) | 0.7768 | | TSH at T1 (mIU/L) | 3.91 (3.08) | 2.33 (1.29) | 0.0222 | | TSH difference T1-T0 (mIU/L) | 1.69 (2.19) | 0.20 (1.00) | 0.0030 | | Endometrial thickness (mm) | 8.3 (1.5) | 8.7 (1.9) | 0.4371 | | Total dose of estradiol administered (mg) | 65 (15) | 72 (33) | 0.5805 | | Duration of estradiol administration (days) | 10.5 (4.3) | 11.0 (4.0) | 0.6727 | | Positive β-hCG test (>5 U/l) (n/total) | 3/10 | 6/24 | 0.7651 |
|
|
Continuous variables are presented as median and (IQR). Significant values are indicated in italics. |
